Robotic mammosphere assay for high-throughput screening in triple-negative breast cancer.
AffiliationSahlgrenska Cancer Center, Goteborgs Universitet, Goteborg, Sweden
MetadataShow full item record
AbstractIn order to identify novel treatment principles specifically affecting cancer stem cells in triple-negative breast cancer, we have developed a high-throughput screening method based on the mammosphere and anoikis resistance assays allowing us to screen compounds using a functional readout. The assay was validated against manual protocols and through the use of positive controls, such as the response to hypoxia and treatment with the known cancer stem cell-targeting compound salinomycin. Manual and robotic procedures were compared and produced similar results in cell handling, cell cultures, and counting techniques, with no statistically significant difference produced from either method. The variance between samples processed manually versus robotically was no greater than 0.012, while Levene's test of significance was 0.2, indicating no significant difference between mammosphere data produced manually or robotically. Through the screening of 989 FDA-approved drugs and a follow-up screen assessing the antineoplastic subgroup, we have identified three therapeutic compounds with the ability to modulate the breast cancer stem cell fraction in the triple-negative breast cancer cell line MDA-MB-231, highlighting their potential usage as stem cell-specific adjuvant treatments.
CitationRobotic mammosphere assay for high-throughput screening in triple-negative breast cancer. 2017, SLAS Discov
- Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
- Authors: Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S
- Issue date: 2015 Jun
- Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
- Authors: Shan NL, Wahler J, Lee HJ, Bak MJ, Gupta SD, Maehr H, Suh N
- Issue date: 2017 Oct
- Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
- Authors: Manupati K, Dhoke NR, Debnath T, Yeeravalli R, Guguloth K, Saeidpour S, De UC, Debnath S, Das A
- Issue date: 2017 Jun
- Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
- Authors: Liu J, Chen X, Ward T, Pegram M, Shen K
- Issue date: 2016 Jul
- Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway.
- Authors: An H, Kim JY, Lee N, Cho Y, Oh E, Seo JH
- Issue date: 2015 Oct 30